VK-2019

Overview

VK-2019 is an orally bioavailable selective inhibitor of EBNA1 . By binding to the protein-DNA interface to interfere with the recruitment and anchoring of the viral DNA replication machinery, VK-2019 effectively blocks the replication and proliferation of EBV in latently infected cells. VK-2019 reduces the copy number and gene expression level of Epstein-Barr virus in tumor cells, decreases the number of EBER -positive cells, and exhibits significant antiviral , immunomodulatory and antiproliferative activities. VK-2019 successfully inhibits tumor growth in EBV-dependent xenograft models. VK-2019 has favorable systemic exposure and acceptable safety profiles, and is widely used in research on advanced nasopharyngeal carcinoma and various EBV -associated cancers.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > EBV

Product Information

• Catalog No.: HY-W725179
• CAS No.: 2044520-06-9
• Molecular Formula: C29H25NO4
• Molecular Weight: 451.51
• Purity: 99.97%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (11.07 mM); Clear solution
• Availability: In-stock

Source

Original product source